‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies
Potential First-In-Class Wnt Agonist
Around half of patients taking anti-VEGF therapies still have fluid on the eye, compromising their vision. • Source: Image archive 
